Polo-Like Kinase 1 is a Therapeutic Target in High-Risk Neuroblastoma

201072 citationsJournal Article

Authors

Sandra Ackermann · University of Cologne

Felix Goeser · University Hospital Heidelberg

Johannes H. Schulte · University of Cologne

Alexander Schramm · University Hospital Cologne

Volker Ehemann · Heidelberg University

Barbara Hero · Heidelberg University

Angelika Eggert ·

Abstract

Elevated PLK1 expression is significantly associated with high-risk neuroblastoma and unfavorable patient outcome. Inhibition of PLK1 using BI 2536 exhibits strong antitumor activity on human neuroblastoma cells in vitro and in vivo, opening encouraging new perspectives for the treatment of high-risk neuroblastoma.

Topics & Keywords

Neuroblastoma Research and Treatments Microtubule and mitosis dynamics Erythrocyte Function and Pathophysiology

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 17, Issue 4, pp. 731-741

DOI: 10.1158/1078-0432.ccr-10-1129

Field-Weighted Citation Impact: 1.77